技術平台

We have developed an innovative acoustic vortex technology VorteSonic for treatment of VTE, with the first go-to-market product of a catheter-based acoustic vortex thrombolytic device. Acoustic vortex produces turbulent flow around the thrombus, resulting in effective thrombolysis by creating loose structure of thrombustherefore enhancing deep penetration of thrombolytic drugs into the thrombus. Advantages of the acoustic vortex technology is reduction of hemorrhagic riskimprovement of safetyprognosis. Feedback system can be integrated for intelligent therapy in the future.

Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.

Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.

The present invention discloses the germplasm bank of medicinal coral producing new targeted anti-cancer agent and their aquaculture technology platform. The medicinal corals are collected in Kenting, located at the southern tip of Taiwan. In response to the unmet medical needs of new anti-cancer drugs, our research results will provide more diverse types of new drug targets and lead compounds in the "new drug development-new drug discovery and exploration period".

SeraParma™ COVID-19 IgM rapid test has high detection sensitivity, which can provide rapid detection of early COVID-19 infection. This SeraParma™ COVID-19 IgM rapid test can detect whether there are IgM antibodies produced in the early stage of infection (within 7 days of symptoms onset) with one drop of the specimen (serumfingertip blood) in 15 minutes by naked eyes compared with LFIA antibody rapid test. It is worth noting that the SeraParma™ COVID-19 IgM rapid test can accurately detect the patients with positive infection within 7 days of the onset of symptoms compared with LFIA.

1. Identification of host factor, which is required for virus replication, by “EditCell Virology Platform”. 2. The host factor will be as a target to develop antivirals. 3. The antiviral effects of the candidates can be validated in vitro and in vivo. 4. Two FDA-approved drugs are repurposed for COVID-19 treatment.

We provide antibody-based solutions to human diseases with short development course at low cost, are based on the phage-displayed GH (Generic Human) synthetic antibody libraries designedconstructed with enabling approaches, leading to the throughput capacities to uplift the innovativenessproductivity in developing antibody therapeuticsdiagnostics. In conjunction with the core technologies, antibody bioinformatics capable of extracting knowledge from big data of human antibody repertoires is used to elucidate human antibody responsesto assist antibody library design.

The "Viral Vaccine Cell Production Technology Platform" of this exhibition is based on 1. Host cell and virus match and colonization technology; 2. Cell-expressed virus receptor technology; 3. Blocking antiviral mechanism of host cell; 4. Immortalization technology of host cell; 5. Serum-free suspension cell culture technology to produce high-immunity virus vaccine strains containing intact virus antigens.

Combined the advanced synchrotron beamline with the in-situ processing technologiesthe diversified measurement systems, we provide a parametrizable AI platform for material manufacturing processes, microstructures,product performance.

We developed a biomimetic triple-antibody-immobilized magnetic fucoidan nanomedicine as a multifunctional artificial antigen presenting cell, which possessed the ability to not only inhibit immune checkpoint but activate tumor infiltrated T cells. of Bridging sites with tunable density on the nanoplatform was designed, allowing the antibodies to be well-distributed on the surface for mimicking immune cells. In contrast to the complex cell expansion process using microbeads in adaptive cell therapy, the nanoplatform can be i.v. administrated to cut the course of therapy from several weeks to days. With the development of the platform technology, an artificial immune system family can be built to pave the way for personalized immunotherapy.

A novel “Platform Technology” in surgical hemostasis, based on biodegradable polyurethane particles with anti-inflammatory and nerve repair, not only accelerates wound healing but also provides solutions for hemostasis during surgery, and improve biocompatibility and adverse of commercially hemostats to achieve the best patient care. Our first product is aimed to provide a hemostatic agent, use on the bleeding surface and deep, with additional functions to surgeons, which allows customers to shorten the operation time, reduce stay in the hospital, and reduce the chance of secondary surgery.